PDK2 and lung carcinoma: Down-regulation of PDK2 can increase the sensitivity of drug-resistant lung cancer cells to paclitaxel, and combining paclitaxel with dichloroacetate (DCA), the specific PDK2 inhibitor, has a synergistic inhibitory effect on the viability of paclitaxel-resistant lung cancer cells.